Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

GILD
Gilead Sciences, Inc.
stock NASDAQ

At Close
1/10/2025 3:59:57 PM EST
89.89USD+0.841%(+0.75)7,697,867
0.00Bid   0.00Ask   0.00Spread
Pre-market
1/10/2025 9:22:30 AM EST
89.99USD+0.954%(+0.85)11,188
After-hours
1/10/2025 4:53:30 PM EST
89.75USD-0.156%(-0.14)145,676
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
10:36AM EST  Earnings Outlook For Gilead Sciences   Benzinga
09:21AM EST  Kite, a Gilead Co. (GILD), said Monday that the U.S. Food and Drug Administration has approved an update to the prescribing information for Yescarta (axicabtagene ciloleucel) to include use of prophylactic corticosteroids across all approved indications.   RTTNews
09:15AM EST  Gilead's Kite Announce FDA Approval Of Update To Prescribing Information For Yescarta   Benzinga
09:04AM EST  Gilead : FDA Approves New Label Update For CAR T-Cell Therapy Yescarta   RTTNews
09:00AM EST  U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta(r) Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome   Business Wire
Jan 28, 2022
12:04PM EST  What 5 Analyst Ratings Have To Say About Gilead Sciences   Benzinga
10:17AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2022   Benzinga
09:15AM EST  Argus Research Upgrades Gilead Sciences to Buy, Announces $75 Price Target   Benzinga
Jan 26, 2022
08:29AM EST  The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data   Benzinga
07:21AM EST  FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings   Benzinga
Jan 25, 2022
08:46PM EST  Gilead Sciences Inc. (GILD) said Tuesday that the U.S. Food and Drug Administration has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions between study arms.   RTTNews
08:20PM EST  Gilead Announces Partial Clinical Hold For Studies Evaluating Magrolimab In Combination With Azacitidine   RTTNews
Jan 24, 2022
10:28PM EST  FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why   Benzinga
09:16AM EST  The U.S. Food and Drug Administration (FDA) has granted approval and reissued the revised Emergency Use Authorization (EUA) to Gilead Sciences Inc. (GILD) for antiviral drug Veklury (remdesivir) to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 disease.   RTTNews
06:11AM EST  A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge   Benzinga
05:52AM EST  FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression   Benzinga
Jan 21, 2022
06:24PM EST  FDA Approves Veklury(r) (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression   Business Wire
05:11AM EST  Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field   Benzinga
Jan 19, 2022
06:03AM EST  Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs   Benzinga
04:58AM EST  Gilead Announced Actions to Remove Counterfeit HIV Medications From U.S. Supply Chain; Gilead Executed Seizures at 17 Locations in Nine States, Seizing Thousands of Bottles of Gilead-labeled Medication With Counterfeit Supply Chain Documentation   Benzinga
Jan 18, 2022
12:24PM EST  Gilead Alleges Counterfeiting Network Sold 85K Bottles Of Its Branded HIV Drugs, Says Some Gilead-Branded Bottles Contained Foreign Tablets Including An Antipsychotic Drug   Benzinga
09:53AM EST  Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $72   Benzinga
06:41AM EST  Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US   Benzinga
Jan 14, 2022
04:50PM EST  Gilead Issues Statement On Zydelig U.S. Indication For Follicular Lymphoma And Small Lymphocytic Leukemia; Says Working With FDA To Complete Withdrawal Of FL, SLL Indications In U.S.   Benzinga
Jan 10, 2022
09:26AM EST  Gilead Sciences, Inc. (GILD) announced Monday that it has entered into two clinical trial collaboration and supply agreements with Merck & Co Inc.(MRK), known as MSD outside the U.S. and Canada.   RTTNews
09:22AM EST  Gilead Sciences Shares Move Higher; CEO Says Remdesivir Working Across All Known Variants Of COVID, Including Omicron; Says Co Working On Oral Form Of Remdesivir, Going Into Early Stage Trials Now   Benzinga
08:42AM EST  Gilead, Merck To Evaluate Trodelvy In Combination With KEYTRUDA In First-Line Metastatic Non-Small Cell Lung Cancer   RTTNews
08:34AM EST  Gilead Announces Clinical Trial Collaborations With Merck To Evaluate Trodelvy In Combination With KEYTRUDA In First-Line Metastatic Non-Small Cell Lung Cancer   Benzinga
08:30AM EST  Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy(r) in Combination With KEYTRUDA(r) in First-Line Metastatic Non-Small Cell Lung Cancer   Business Wire
Jan 6, 2022
10:13AM EST  What 5 Analyst Ratings Have To Say About Gilead Sciences   Benzinga
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022   Benzinga
08:02AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
06:02AM EST  Morgan Stanley Downgrades Gilead Sciences to Equal-Weight, Lowers Price Target to $74   Benzinga
Dec 23, 2021
07:29AM EST  The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review   Benzinga
06:17AM EST  Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19   Benzinga
Dec 22, 2021
10:13PM EST  Gilead Sciences Inc.'s (GILD) veklury or remdesivir significantly reduced risk of hospitalization in high-risk patients with COVID-19, as per results from a phase 3 investigational study.   RTTNews
05:08PM EST  Gilead Reports New England Journal Of Medicine Published Data Showing Veklury Reduced Risk Of Hospitalization In High-Risk Patients With COVID-19   Benzinga
05:08PM EST  Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury(r) (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19   Business Wire
10:09AM EST  Price To Earnings Ratio Insights For Gilead Sciences   Benzinga
08:14AM EST  FDA Slaps Clinical Hold On Gilead's Injectable Lenacapavir In HIV Trials   Benzinga
07:42AM EST  The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda   Benzinga
04:58AM EST  Gilead on Tuesday Announced Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns   Benzinga
Dec 21, 2021
09:08PM EST  Gilead Sciences Inc. (GILD) said that the U.S. Food and Drug Administration has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis.   RTTNews
07:59PM EST  Gilead Announces Clinical Hold On Studies Evaluating Injectable Lenacapavir For HIV Treatment And Prevention   RTTNews
07:12PM EST  Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns   Business Wire
04:52PM EST  Gilead, Arcus Biosciences Complete Closing Of Option Exercise For 3 Clinical-Stage Programs And New Research Collaboration   Benzinga
04:35PM EST  Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration   Business Wire
09:45AM EST  European Commission Expands Use Of Remdesivir In COVID-19 Patients Not On Supplemental Oxygen   Benzinga
05:04AM EST  Gilead Sciences, Inc. (GILD) announced Tuesday that the European Commission has approved a variation to the Conditional Marketing Authorization for Veklury (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19.   RTTNews
04:34AM EST  Gilead Announced European Commission Expanded Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression; Said Laboratory Findings Suggest Veklury Will Continue to Be Active vs Omicron Variant   Benzinga
04:13AM EST  Gilead Sciences: EC Approves A Variation To The Conditional Marketing Authorization For Veklury   RTTNews
04:00AM EST  European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression   Business Wire
Dec 17, 2021
12:07PM EST  UPDATE: Gilead's Veklury Receives Positive CHMP Opinion For Treatment Of Adults Not On Supplemental Oxygen And Considered High Risk For COVID-19 Progression   Benzinga
09:53AM EST  EMA Might Not Decide On Merck's COVID-91 Oral Antiviral Before Christmas: Reuters   Benzinga
07:29AM EST  EMA Said CHMP Recommended Extending the Use of Covid-19 Treatment Veklury (Remdesivir) to Include Adults at Increased Risk of Severe Covid-1   Benzinga
Dec 16, 2021
06:01PM EST  Gilead's Kite, Daiichi Sankyo Report Authorized First YESCARTA CAR T-Cell Therapy Treatment Site In Japan   Benzinga
06:00PM EST  Daiichi Sankyo Authorizes the First YESCARTA(r) (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan   Business Wire
10:14AM EST  Guild Esports PLC: Trading Commences on the OTCQB Venture Market in the United States   Business Wire
Dec 14, 2021
06:39AM EST  Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients   Benzinga
Dec 13, 2021
02:50PM EST  Gilead's Kite Highlights 'Yescarta ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma'   Benzinga
02:45PM EST  Yescarta(r) ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma   Business Wire
06:26AM EST  Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients   Benzinga
Dec 11, 2021
10:05AM EST  Kite, a Gilead Company (GILD), said that yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma.   RTTNews
10:00AM EST  Yescarta(r) Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma   Business Wire
09:17AM EST  Gilead's Kite Announced Yescarta Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma; Said 42.6% of Study Patients Alive at Five Years Following a Single Infusion of Yescarta   Benzinga
09:00AM EST  Yescarta(r) Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma   Business Wire
08:59AM EST  Kite: Yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration In Refractory Large B-Cell Lymphoma   RTTNews
08:30AM EST  Yescarta(r) CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma   Business Wire
Dec 10, 2021
09:14AM EST  Biopharmaceutical company Gilead Sciences, Inc. (GILD) on Friday announced results of a Phase 3 study that showed clinical benefit for Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) in patients who received two or more prior systemic therapies, at least one of them for metastatic disease.   RTTNews
08:41AM EST  'House Democrats find in three-year investigation that drug prices are 'unsustainable, unjustifiable and unfair'' -Washington Post   Benzinga
08:05AM EST  Gilead:Trodelvy Shows Clinical Benefit For Black Patients Consistent With Full Metastatic Triple-Negative Breast Cancer   RTTNews
08:01AM EST  Gilead Reports Trodelvy Showed Clinical Benefit For Black Patients Consistent With Full Metastatic Triple-Negative Breast Cancer Population In ASCENT Study   Benzinga
08:00AM EST  Trodelvy(r) Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study   Business Wire
Dec 9, 2021
09:50PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021   Benzinga
09:47PM EST  Wells Fargo Initiates Coverage On Gilead Sciences with Equal-Weight Rating, Announces Price Target of $72   Benzinga
Dec 7, 2021
08:26AM EST  The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Dar   Benzinga
Dec 6, 2021
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021   Benzinga
06:30AM EST  Goldman Sachs Initiates Coverage On Gilead Sciences with Neutral Rating, Announces Price Target of $80   Benzinga
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
06:00AM EST  Gilead Recalls Two Lots Of Remdesivir Due To Presence Of Glass Particulates   Benzinga
Dec 3, 2021
04:34PM EST  Gilead Issues Voluntary Nationwide Recall Of 2 Lots Of Veklury Due To Presence Of Glass Particulates   Benzinga
Nov 30, 2021
04:48PM EST  Watching COVID-19 Antibody Drug Stocks; Wall Street Journal Earlier Reports 'Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates'   Benzinga
Nov 29, 2021
09:09AM EST  Gilead, AWS Collaborate On Development And Delivery Of New Medicines For Patients   Benzinga
08:31AM EST  Gilead Says Co's Bold Ambition Of Transforming Triple-Negative Breast Cancer Treatment To Be Highlighted With New Data At SABCS   Benzinga
08:30AM EST  Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS   Business Wire
Nov 24, 2021
10:01AM EST  A Look Into Gilead Sciences Debt   Benzinga
09:33AM EST  Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial   Benzinga
Nov 23, 2021
01:03PM EST  Gilead's Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer   Benzinga
08:53AM EST  Gilead Sciences, Inc. (GILD) said the European Commission has granted marketing authorization for Trodelvy, a first-in-class Trop-2-directed antibody-drug conjugate, as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer.   RTTNews
08:35AM EST  Gilead : Trodelvy Granted Marketing Authorization In EU For Metastatic Triple-Negative Breast Cancer Treatment   RTTNews
08:31AM EST  Gilead Announces Trodelvy Granted European Commission Marketing Authorization For Treatment Of Metastatic Triple-Negative Breast Cancer In Second Line   Benzinga
08:30AM EST  Trodelvy(r) (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line   Business Wire
08:10AM EST  The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug   Benzinga
Nov 19, 2021
12:36PM EST  Gilead Files US Application For Bulevirtide In Severe Form Of Viral Hepatitis   Benzinga
08:38AM EST  Pharmaceutical firm Gilead Sciences, Inc. (GILD), on Friday, said it has submitted a Biologics License Application or BLA, to the U.S. Food and Drug Administration or FDA, for bulevirtide 2 mg injection, a potential first-in-class antiviral medicine for the treatment of chronic hepatitis delta virus or HDV infection in adults with compensated liver disease.   RTTNews
08:07AM EST  Gilead Submits BLA To FDA For Bulevirtide, Investigational Treatment For People Living With Chronic Hepatitis Delta   RTTNews
08:04AM EST  Gilead Reports Submission Of Its Biologics License Application To FDA For Bulevirtide Treatment For People Living With Chronic Hepatitis Delta   Benzinga
08:00AM EST  Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta   Business Wire
Nov 18, 2021
07:23AM EST  Gilead Exercises Options To Three Arcus Biosciences Clinical-stage Programs And Adds Research Collaboration; Arcus To Receive Option Payments Totaling $725M   Benzinga
07:00AM EST  Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration   Business Wire
Nov 12, 2021
06:02PM EST  S&P Dow Jones Indices Announces Dow Jones Sustainability Indices 2021 Review   PR Newswire
Nov 11, 2021
08:03AM EST  The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts   Benzinga
Nov 10, 2021
08:45PM EST  Gilead Sciences Inc. (GILD) said that the Everest Medicines sponsored Phase 2b EVER-132-001 study of sacituzumab govitecan, which is marketed as Trodelvy in the United States, met its primary endpoint of overall response rate in metastatic triple-negative breast cancer.   RTTNews
08:06PM EST  Gilead : Phase 2b Study Of Sacituzumab Govitecan In China Of Patients With Metastatic TNBC Meets Primary Endpoint   RTTNews
07:00PM EST  Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint   Business Wire
Nov 9, 2021
12:02PM EST  Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting Nov. 12-15   Benzinga
11:53AM EST  Gilead Granted U.S. Patent 'Antibodies that target HIV GP120 and methods of use'   Benzinga
10:00AM EST  Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting(r)   Business Wire
Nov 5, 2021
05:26PM EDT  Will Pfizer Outgun Merck With Oral COVID-19 Pill?   Benzinga
Nov 4, 2021
09:44AM EDT  Gilead, Kite Oncology Will Showcase Pipeline In Cell Therapy, Blood Cancer At American Society Of Hematology Dec. 11-13   Benzinga
09:23AM EDT  Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline   Business Wire
Nov 2, 2021
11:25AM EDT  Gilead Sciences Option Alert: Jun 17 $75 Calls Sweep (14) near the Ask: 150 @ $1.781 vs 41226 OI; Ref=$65.44   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 29, 2021
01:02PM EDT  UPDATE: SVB Leerink On Gilead Price Target Cut: Firm Notes Mgmt 'Sees Underlying Demand In HIV Market Recovering Slowly' At +3% Q/Q; Co. Currently Holds 75% Of Treatment Market Share But Firm Sees Revenue & Adj EPS Declining 0.4-0.5% CAGR Through FY25   Benzinga
08:00AM EDT  The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs   Benzinga
07:40AM EDT  Gilead : Data In People Living With HIV On Biktarvy In BICSTaR Study Shows Consistent Efficacy Profile   RTTNews
07:31AM EDT  Gilead Sciences Says Clinical, Patient-Reported Outcomes In People Living With HIV On Biktarvy In Observational BICSTaR Study Demonstrate Consistent Efficacy Profile In Real-World Setting   Benzinga
07:30AM EDT  Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy(r) in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting   Business Wire
06:39AM EDT  SVB Leerink Maintains Outperform on Gilead Sciences, Lowers Price Target to $75   Benzinga
06:33AM EDT  Gilead Trims Non-COVID Product Sales Outlook, Though Q3 Earnings Beat Street Estimates   Benzinga
Oct 28, 2021
06:03PM EDT  Biotechnology company Gilead Sciences, Inc. (GILD) on Thursday raised its outlook for fiscal 2021, helped by strong performance in the third quarter.   RTTNews
04:59PM EDT  Gilead Sciences Inc. (GILD) revealed earnings for its third quarter that rose from the same period last year.   RTTNews
04:49PM EDT  Gilead Sciences Q3 EPS $2.05 Vs. $0.29 Year Ago   RTTNews
04:41PM EDT  Recap: Gilead Sciences Q3 Earnings   Benzinga
04:19PM EDT  Gilead Enters Clinical Trial Collaboration With Merck To Evaluate Trodelvy In Combination With KEYTRUDA   RTTNews
04:10PM EDT  Gilead Reports Trial Collab With Merck To Evaluate Trodelvy In Combo With KEYTRUDA In Patients with First-Line Metastatic Triple-Negative Breast Cancer   Benzinga
04:10PM EDT  Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy(r) (sacituzumab govitecan-hziy) in Combination With KEYTRUDA(r) (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer   Business Wire
04:04PM EDT  UPDATE: Gilead Raises FY21 Sales Guidance From $24.4B-$25B To $26B-$26.3B vs $25.1B Est., Adj. EPS From $6.90-$7.25 To $7.90-$8.10 vs $7.18 Est.   Benzinga
04:03PM EDT  Gilead Raises Guidance   Benzinga
04:03PM EDT  Gilead Sciences Q3 EPS $2.65 Beats $1.74 Estimate, Sales $7.40B Beat $6.25B Estimate   Benzinga
04:08AM EDT  Earnings Scheduled For October 28, 2021   Benzinga
Oct 27, 2021
10:25AM EDT  Gilead Sciences Earnings Preview   Benzinga
Oct 26, 2021
08:36AM EDT  The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children   Benzinga
06:49AM EDT  Gilead, Merck Begin Phase 2 Study Evaluating Lenacapavir With Islatravir For HIV-1 In Virologically Suppressed Adults   RTTNews
06:48AM EDT  Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults   Benzinga
Oct 21, 2021
12:11PM EDT  Gilead Highlights Presentation Of Long-Term Switch Data Reinforcing Biktarvy As Treatment Option For Broad Range Of People Living With HIV   Benzinga
07:37AM EDT  Gilead Presents Long-Term Switch Data Reinforcing Biktarvy(r) as a Treatment Option for a Broad Range of People Living With HIV   Business Wire
Oct 19, 2021
09:41AM EDT  Gilead Sciences Inc. (GILD) said Tuesday that it will donate 100,000 vials of Veklury or remdesivir to help address the recent surge of COVID-19 cases in Indonesia and 3,000 vials of Veklury to help patients hospitalized with COVID-19 in Armenia.   RTTNews
08:38AM EDT  Gilead Sciences To Donate 100,000 Vials Of Remdesivir To Help Address COVID-19 Crisis In Indonesia And Armenia   RTTNews
08:30AM EDT  Gilead Sciences Announces Veklury(r) Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia   Business Wire
Oct 18, 2021
07:47AM EDT  Gilead Sciences, Inc. (GILD) announced the FDA approved a new low-dose tablet dosage form of Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. The company said this approval expands the indication for Biktarvy to include younger children living with HIV-1 infection.   RTTNews
07:35AM EDT  Gilead Sciences Says FDA Approves Expanded Indication Of Biktarvy For Treatment Of HIV-1 In Pediatric Populations   RTTNews
07:34AM EDT  Gilead Announces FDA Approval Of Biktarvy For Treatment Of HIV-1 In Pediatric Populations   Benzinga
07:30AM EDT  U.S. Food and Drug Administration Approves Expanded Indication of Gilead's Biktarvy(r) for Treatment of HIV-1 in Pediatric Populations   Business Wire
Oct 15, 2021
08:20AM EDT  GILD : Sacituzumab Govitecan Gets Positive CHMP Opinion   RTTNews
08:05AM EDT  Gilead : Sacituzumab Govitecan Gets Positive CHMP Opinion As 2L Treatment For Metastatic Triple-Negative Breast Cancer   RTTNews
08:02AM EDT  Gilead Sciences Says Sacituzumab Govitecan Receives Positive CHMP Opinion As 2L Treatment For Adult Patients With Metastatic Triple-Negative Breast Cancer   Benzinga
08:00AM EDT  Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer   Business Wire
06:55AM EDT  - EMA Recommended Granting a Marketing Authorisation in the European Union for Gilead's Trodelvy (Sacituzumab Govitecan)   Benzinga
Oct 14, 2021
04:10PM EDT  Gilead To Report Q3 Earnings On Thursday, Oct. 28, 2021 After Market Close   Benzinga
12:00PM EDT  This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers   Benzinga
Oct 13, 2021
03:41PM EDT  Gilead Sciences Option Alert: Jan 21 $75 Calls Sweep (42) above Ask!: 276 @ $0.949 vs 7008 OI; Earnings 10/27 After Close [est] Ref=$67.58   Benzinga
Oct 12, 2021
08:23AM EDT  Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $84   Benzinga
06:00AM EDT  Molnupiravir? Not So Fast. What About Tollovir? Here's Why You Should Know What That Means   Benzinga
Oct 5, 2021
08:32AM EDT  NanoViricides Leaps Forward in its Quest to Defeat COVID-19   Benzinga
Oct 4, 2021
10:21AM EDT  Tesla and Merck Give Investors Some Hope   Benzinga
Oct 1, 2021
05:46PM EDT  U.S. FDA Approves Kite's Tecartus(r) as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia   Business Wire
02:29PM EDT  Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates   Benzinga
08:46AM EDT  Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting   Benzinga
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 30, 2021
04:54PM EDT  Gilead Says Kite Submits Supplemental Biologics License Application To FDA For Earlier Use Of Yescarta In Large B-cell Lymphoma   Benzinga
04:50PM EDT  Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta(r) in Large B-cell Lymphoma   Business Wire
Sep 29, 2021
05:10PM EDT  Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show   Benzinga
Sep 28, 2021
09:27AM EDT  Gilead Scores Fifth Approval For Trodelvy In Triple-Negative Breast Cancer, This Time In Canada   Benzinga
01:26AM EDT  Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus   Benzinga
Sep 27, 2021
04:36PM EDT  Gilead Marks Fifth Approval For Trodelvy In Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative With Health Canada Authorization   Benzinga
11:41AM EDT  Gilead Sciences Issues Statement On New NCCN Clinical Practice Guidelines In Oncology Recommendations For Sacituzumab Govitecan-HZIY In Second-Line And Later Metastatic Triple-Negative Breast Cancer   Benzinga
05:53AM EDT  Acceleron In Advanced $11B Buyout Talks: Bloomberg   Benzinga
Sep 24, 2021
11:56AM EDT  7 Members Of Congress Failed To Disclose Stock Transactions: Who Was Named, And What's Next?   Benzinga
Sep 22, 2021
12:36PM EDT  Gilead's Remdesivir Cuts Risk of Hospitalization In High-Risk COVID-19 Patients   Benzinga
09:41AM EDT  Gilead Says Veklury Significantly Reduced Risk Of   RTTNews
09:09AM EDT  Gilead :late-stage Trial Results Show Remdesivir Reduces Risk Of Hospitalization In High-Risk Patients With COVID-19   RTTNews
09:01AM EDT  Veklury(r) (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19   Business Wire
08:33AM EDT  UPDATE: Gilead Says Veklury Showed Statistically Significant Reduction Of 87% Related To Risk Of Composite Primary Endpoint Of COVID-19-Related Hospitalization   Benzinga
08:33AM EDT  Gilead Says Its Veklury (Remdesivir) Reduced Risk Of Hospitalization In High-Risk Patients with COVID-19   Benzinga
Sep 21, 2021
06:15AM EDT  EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile   Benzinga
Sep 20, 2021
08:35AM EDT  Gilead To Present Latest Antiviral Research Data Addressing Urgent Global Needs In Infectious Disease At IDWeek 2021   Benzinga
08:35AM EDT  Gilead Sciences Announces Upcoming Presentation Of New Data From Virology Research And Development Programs   RTTNews
08:30AM EDT  Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021   Business Wire
Sep 18, 2021
04:24PM EDT  Barron's Latest Picks And Pans: Apple, Bitcoin, a Goldman Sachs ETF, Nike And More   Benzinga
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
Sep 16, 2021
12:49PM EDT  Gilead Churns Out Additional Trodelvy Data   Benzinga
07:31AM EDT  Gilead: New Data Shows Survival Benefit With Trodelvy -   RTTNews
07:06AM EDT  Gilead Sciences Announces New Data From Phase 3 ASCENT Study Of Trodelvy   RTTNews
07:01AM EDT  Gilead Announces New Data From Phase 3 ASCENT Study Of Trodelvy Showing 'significant and clinically meaningful improvements in health-related quality of life'   Benzinga
07:00AM EDT  Trodelvy(r) Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study   Business Wire
07:00AM EDT  New Data Demonstrate Trodelvy(r) Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status   Business Wire
Sep 13, 2021
08:34AM EDT  Gilead Sciences To Present Data At ESMO Congress 2021 Reinforcing Practice-changing Potential Of Trodelvy   RTTNews
08:30AM EDT  Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy   Business Wire
Aug 31, 2021
10:10AM EDT  A Look Into Gilead Sciences Debt   Benzinga
Aug 26, 2021
12:58PM EDT  Gilead Wins Reversal of $1.2B Patent Loss to Bristol-Myers: Bloomberg   Benzinga
Aug 24, 2021
01:22PM EDT  Siemens' Fatty Liver Disease Blood Test Wins FDA De Novo Clearance   Benzinga
Aug 19, 2021
04:16PM EDT  European Medicines Agency Validates Gilead's Marketing Authorization Application For Lenacapavir, An Investigational, Long-acting Capsid Inhibitor For The Treatment Of Hiv-1 In People With Limited Therapy Options   Benzinga
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
01:50PM EDT  Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma   Benzinga
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
11:02AM EDT  What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months   Benzinga
Aug 6, 2021
04:04PM EDT  Fake Versions Of Gilead's HIV Drugs Are In Circulation In US   Benzinga
Aug 5, 2021
06:30PM EDT  Gilead Sciences Says Co Has Become Aware Of Tampered And Counterfeit Versions Of Its HIV Treatment And Prevention Medication   Benzinga
09:51AM EDT  Biopharmaceutical company Kite, a unit of Gilead Sciences, Inc. (GILD) singularly focused on cell therapy for cancer treatment, and Appia Bio, Inc., an early-stage biotechnology company developing cancer therapies, on Thursday announced a collaboration and license agreement to research and develop Hematopoietic Stem Cells derived therapies for hematological malignancies.   RTTNews
08:41AM EDT  Kite And Appia Bio Announce Collaboration To Research And Develop Allogeneic Cell Therapies For Cancer   RTTNews
08:38AM EDT  UPDATE: Gilead's Kite To Pay Appia Bio Upfront Payment, Equity Investment, Added Milestones For Total Value Up To $875M As Well As Tiered Royalties   Benzinga
08:38AM EDT  Gilead's Kite Reports Collaboration Deal With Appia Bio To Research, Develop Allogeneic Cell Therapies For Cancer   Benzinga
Aug 4, 2021
07:07AM EDT  BioNTech Closes Acquisition Of Kite's Neoantigen TCR Cell Therapy R&D Facility In Gaithersburg, Maryland   RTTNews
07:00AM EDT  BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland   Business Wire
Aug 3, 2021
11:02AM EDT  Gilead Sciences Announces More Than $200 Mln Endowment To Gilead Foundation   RTTNews
10:45AM EDT  Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program   Business Wire
Jul 30, 2021
10:05AM EDT  RBC Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $84   Benzinga
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
07:11AM EDT  SVB Leerink Maintains Outperform on Gilead Sciences, Raises Price Target to $77   Benzinga
Jul 29, 2021
10:27PM EDT  Gilead Sciences Inc. (GILD) said it now expects GAAP earnings per share for the fiscal year 2021 to between $4.70 and $5.05, compared to the prior estimation of $4.75 to $5.45.   RTTNews
05:19PM EDT  Gilead Sciences Q2 EPS $1.21 Vs. Loss $2.66 Year Ago   RTTNews
05:09PM EDT  Gilead Sciences Says Won't Move Forward With Inhaled Version Of Remdesivir   Benzinga
04:48PM EDT  Recap: Gilead Sciences Q2 Earnings   Benzinga
04:03PM EDT  Gilead Sees FY21 Adj. EPS $6.90-$7.25 vs $7.07 Estimate, Sales $24.4B-$25B vs $24.64B Estimate   Benzinga
04:02PM EDT  Gilead Sciences Q2 Adj. EPS $1.87 Beats $1.73 Estimate, Sales $6.20B Beat $6.07B Estimate   Benzinga
01:37PM EDT  Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients   Benzinga
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
04:23AM EDT  Earnings Scheduled For July 29, 2021   Benzinga
Jul 26, 2021
02:24PM EDT  Gilead Ordered To Pay Attorney Fees In Shareholder Lawsuit   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 19, 2021
10:28AM EDT  BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum   Benzinga
09:02AM EDT  German biotechnology company BioNTech SE (BNTX) Monday announced that it has entered into a purchase agreement with Kite, a Gilead Company (GILD). Under the deal, BioNTech will acquire Kite's solid tumor neoantigen T cell receptor or TCR R&D platform and clinical manufacturing facility in Gaithersburg, MD. Financial terms of the deal were not disclosed.   RTTNews
08:03AM EDT  BioNTech To Buy Kite's Neoantigen TCR Cell Therapy R&D Platform And Manufacturing Facility In Gaithersburg   RTTNews
08:02AM EDT  BioNTech To Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform And Manufacturing Facility In Gaithersburg, MD; Financial Terms Not Disclosed   Benzinga
08:00AM EDT  BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD   Business Wire
06:17AM EDT  Four-Year Biktarvy Data Show High Efficacy, Durable Viral Suppression In Untreated HIV Patients   Benzinga
06:06AM EDT  Gilead's Lenacapavir Shows High Rates Of Virologic Suppression In Heavily Treated HIV Patients   Benzinga
Jul 17, 2021
06:01AM EDT  Four-Year Biktarvy(r) Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Nave Adults   Business Wire
06:01AM EDT  New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor   Business Wire
Jul 15, 2021
04:08PM EDT  Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021   Benzinga
Jul 13, 2021
06:06AM EDT  Gilead's Remdesivir Fails To Show Antiviral Effects Against COVID-19 In Small WHO Study   Benzinga
Jul 12, 2021
07:34AM EDT  Gilead To Present Abstracts At IAS 2021   Benzinga
07:30AM EDT  Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research   Business Wire
Jun 30, 2021
04:34PM EDT  Donald Rumsfeld, Two-Time Defense Secretary, Dies At 88   Benzinga
Jun 29, 2021
03:07PM EDT  Gilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal   Benzinga
08:17AM EDT  The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout   Benzinga
Jun 28, 2021
04:10PM EDT  Gilead Submits New Drug Application To FDA For Lenacapavir For The Treatment Of HIV-1   Benzinga
04:09PM EDT  Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options   Business Wire
09:48AM EDT  Gilead's Yescarta Touts Positive Data In Second-Line Large B-Cell Lymphoma Patients   Benzinga
09:13AM EDT  Kite's CAR T-cell Therapy Improves Survival By 60% Over   RTTNews
08:35AM EDT  Kite Says ZUMA-7 Study Meets Primary Endpoint Of Event-free survival, Secondary Endpoint Of Objective Response Rate   RTTNews
08:32AM EDT  Gilead's Kite Announces Yescarta CAR T-cell Therapy Improved Event-Free Survival By 60% Over Chemotherapy Plus Stem Cell Transplant In Second-Line Relapsed Or Refractory Large B-cell Lymphoma   Benzinga
08:30AM EDT  Kite Announces Yescarta(r) CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma   Business Wire
Jun 24, 2021
09:29AM EDT  Gilead Sciences Inc. (GILD) said that treatment with hepcludex or bulevirtide was shown to achieve significant response in chronic hepatitis delta virus after 24 weeks. Interim phase 2b and phase 3 data are consistent with previous results and reinforce the clinical profile of hepcludex in adults with chronic HDV and compensated liver disease.   RTTNews
09:07AM EDT  Gilead Announces Interim Results From Phase 2b And Phase 3 clinical Trials Evaluating Hepcludex   RTTNews
09:01AM EDT  Gilead Reports Interim Results From Phase 2b/Phase 3 Trials Of Its Chronic Hep Delta Virus Treatment Were Consistent With Previous Results   Benzinga
09:00AM EDT  Treatment With Hepcludex(r) (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC